Historical Stock Chart
3 Months : From Jan 2020 to Apr 2020
By Anthony O. Goriainoff
AstraZeneca PLC (AZN.LN) said on Monday that the Phase 2 trial for Enhertu, its gastric cancer drug, met its primary endpoint.
The U.K. pharmaceutical company said the trial met the primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer compared to an investigator's choice of chemotherapy.
"Given the previous results seen in our HER2-positive development program and now in HER2-positive metastatic gastric cancer, we believe this antibody drug conjugate has the potential to redefine the treatment of patients with HER2-expressing cancers," the company said.
Write to Anthony O. Goriainoff at email@example.com
(END) Dow Jones Newswires
January 27, 2020 02:43 ET (07:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.